Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643-1656.
[3]
Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428-1436.
[4]
Kaufman DW, Kelly JP, Jurgelon JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl. 1996;60:23-30.
[5]
Dingli D, Tefferi A. Drug-induced aplastic anemia: pathogenesis and clinical aspects. Mayo Clin Proc. 2000;75(7):719-724.
[6]
Heimpel H. Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood. 2001;98(13):3597-3598.
[7]
Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Blood and Marrow Transplant (EBMT) group. Haematologica. 2007;92(1):11-18.
[8]
Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185-1196.
[9]
Risitano AM. Immunosuppressive therapy in aplastic anemia: anti-thymocyte globulin (ATG) and cyclosporine. Ann Hematol. 2020;99(3):477-484.
[10]
Peslak SA, Olson T, Babushok DV. Diagnosis and treatment of aplastic anemia. Curr Opin Hematol. 2017;24(6):509-515.